Effector CD8+ T cells in the tumor microenvironment generate Interleukin-2 (IL-2), IL-12 and Interferon-γ (IFN-γ), which enhance CD8+ CTLs, leading to targeted tumor cell killing (35, 36). Here, IL2 is linked to neoplasm.